Key Findings To Date
The Inflation Reduction Act (IRA)
- The OOP average cost increased in total for all of the MFP medicines that were included in the analysis when comparing 1Q2025 to 1Q2024 and 2Q2025 to 2Q2024.
- The average OOP cost across all nine MFP drugs increased by $22.86 comparing 1Q2025 to 1Q2024 and $2.12 comparing 2Q2025 to 2Q2024.
- The average OOP cost for all nine MFP medicines increased by 31% comparing 1Q2025 to 1Q2024 and increased 3.4% comparing 2Q2025 to 2Q2024.
- The OOP costs increased specifically for seven of the nine medicines with a negotiated MFP in both quarterly analyses. However, the increases were not the same medicines in each quarter.
- Cost increases ranged from $10.56 to $316.81.
- Of the two medicines that did not have OOP increases, one faced new competition from biosimilars that only became available in 2025. All four of the largest PBMs increased OOP costs for six of the seven medicines with cost increases; one medication had OOP increases from only three of these PBMs.